ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 23/07/2024 BST 5-day change 1st Jan Change
332.23 USD -2.27% Intraday chart for ICON Public Limited Company -4.04% +17.37%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : ICON Public Limited Company Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 01:30 PM
Baird Adjusts Price Target on ICON to $367 From $363, Maintains Outperform Rating MT
Transcript : ICON Public Limited Company - Analyst/Investor Day
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024 CI
Diamyd Medical AB Appoints ICON plc to Conduct Interim Analysis for the Phase 3 Trial CI
ICON Prices $2 Billion Debt Offering MT
ICON Public Limited Company Announces Pricing of USD 2 Billion Notes CI
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating MT
ICON Seeks M&A CI
Transcript : ICON Public Limited Company, Q1 2024 Earnings Call, Apr 25, 2024
ICON Q1 Adjusted EPS, Revenue Rise, 2024 Guidance Range Narrowed MT
Earnings Flash (ICLR) ICON Reports Q1 EPS $3.47, vs. Street Est of $3.41 MT
Earnings Flash (ICLR) ICON Reports Q1 Revenue $2.09B, vs. Street Est of $2.088B MT
Icon Public Limited Company Updates Earnings Guidance for the Year 2024 CI
ICON Public Limited Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Icon CFO Brennan to Depart for Outside Opportunity DJ
Icon Says CFO Brennan Leaving in Q4, Reaffirms Guidance MT
Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024 CI
Icon plc Reaffirm Earnings Guidance for the Year 2024 CI
Transcript : ICON Public Limited Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:05 PM
Transcript : ICON Public Limited Company Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Evercore ISI Adjusts Price Target on ICON to $350 From $325, Keeps Outperform Rating MT
UBS Adjusts ICON Price Target to $368 From $295, Maintains Buy Rating MT
Mizuho Securities Ups Price Target on ICON to $346 From $315, Keeps Buy Rating MT
Barclays Adjusts Price Target on ICON to $355 From $325, Maintains Overweight Rating MT
Chart ICON Public Limited Company
More charts
Logo ICON Public Limited Company
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
Employees
41,150
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
332.23USD
Average target price
364.20USD
Spread / Average Target
+9.62%
Consensus
  1. Stock Market
  2. Equities
  3. ICLR Stock
  4. News ICON Public Limited Company
  5. UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating